Observational studyClinical cardiology2019
Cardiovascular events and death after myocardial infarction or ischemic stroke in an older Medicare population.
Observational study in Clinical cardiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- Association Between Circulating Proprotein Convertase Subtilisin/Kexin Type 9 Concentrations and Cardiovascular Events in Cardiovascular Disease: A Systemic Review and Meta-Analysis.Frontiers in cardiovascular medicine · 2021Pooled it
- Cardiometabolic outcomes with dapagliflozin after myocardial infarction by baseline ejection fraction: DAPA-MI.ESC heart failure · 2025Trial
- Updated Cost-effectiveness Analysis of Evolocumab in Patients With Very High-risk Atherosclerotic Cardiovascular Disease.JAMA cardiology · 2019 · on this mapTrial
- Conformity with guideline-directed medical therapy and clinical outcomes in secondary cardiovascular prevention-results of a German claims data analysis.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Measurement of Active Thrombin Bound to Circulating D-Dimers as a Sensitive Biomarker for Prothrombotic Conditions.Journal of clinical laboratory analysis · 2026Article
- Combination Lipid-Lowering Therapy After ACS: Should this be the New Standard of Care?Current cardiology reports · 2026Review
- Early Health Technology Assessment (HTA) of Olpasiran and Pelacarsen for Secondary Prevention of Coronary Heart Disease (CHD).ClinicoEconomics and outcomes research : CEOR · 2026Article
- Home-Based Cardiac Rehabilitation in Cardiovascular Diseases: A Narrative Review of Progress, Challenges, and Future Directions.Journal of multidisciplinary healthcare · 2026Review
- Potential Bias in Self-Controlled Case Series Design: Impact of Incident Versus Prevalent Scenarios of Exposure and Outcome.Pharmacoepidemiology and drug safety · 2025Article
- Cost-Effectiveness of the CADScor System in Low-Risk Patients Presenting to the Emergency Department with Chest Pain.PharmacoEconomics - open · 2025Article
- The Holy Grail of cardiology?Experimental physiology · 2025Article
- High-Tyrosol/Hydroxytyrosol Extra Virgin Olive Oil Enhances Antioxidant Activity in Elderly Post-Myocardial Infarction Patients.Antioxidants (Basel, Switzerland) · 2025Article
- Incorporating the STOP-BANG questionnaire improves prediction of cardiovascular events during hospitalization after myocardial infarction.Scientific reports · 2025Article
- Cardioprotective Effects of Adiponectin-Stimulated Autophagy.Journal of lipid and atherosclerosis · 2025Review
- FOS as a biomarker for myocardial infarction treatment with Deng's Yangxin Decoction: a systems biology-based analysis.Frontiers in cardiovascular medicine · 2025Article
- Immunization and cardiovascular disease in Latin America. The CorVacc study: rationale and design.Archivos de cardiologia de Mexico · 2025Article
- Cost-Utility Analysis of Low-Dose Pioglitazone in a Population With Prediabetes and a History of Stroke or Transient Ischemic Attack.Journal of the American Heart Association · 2024Article
- Recurrent Atherosclerotic Cardiovascular Disease Events Potentially Prevented with Guideline-Recommended Cholesterol-Lowering Therapy following Myocardial Infarction.Cardiovascular drugs and therapy · 2024Article
- The relative impact of components of high residual risk on the long-term prognosis after AMI.International journal of cardiology. Cardiovascular risk and prevention · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSurvivors of myocardial infarction (MI) or ischemic stroke (IS) are at high risk for subsequent cardiovascular events. HYPOTHESIS: Older patients with prior MI or IS are at risk for recurrent cardiovascular events, and comorbidities such as diabetes may increase this risk.
methodsTwo cohorts were studied in a retrospective Medicare 20% random sample-a 2008 cohort with up to 6 years of follow-up (MI, N = 26 460; IS, N = 17 566) and a 2012 cohort with 1 year of follow-up (MI, N = 26 548; IS, N = 17 728).
resultsIn older patients who survived an event of MI or IS (2012 cohort), 7.2% had a recurrent MI and 6.7% had a recurrent IS in the first year; 32% died. Accounting for multiple recurrent events (2012 cohort), the event rates per 100 patient-years were 11.6 and 10.2 for the MI and IS cohorts, respectively. Cumulative incidence of recurrence (2008 cohort) increased from 7.7% at 1 year to 14.3% at 6 years for recurrent MI and from 6.7% at 1 year to 13.4% at 6 years for recurrent IS. Comorbid diabetes (2012 cohort) was significantly associated (adjusted risk ratio) with MI recurrence (1.44) and risk of coronary revascularization (1.23) in the MI cohort and with IS recurrence (1.26) in the IS cohort.
conclusionIn this older population with prior MI or IS, high rates of recurrent cardiovascular events and multiple recurrent events were observed. These findings highlight the need for aggressive intervention for secondary prevention and management of comorbidities in high-risk patients, particularly those with diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.